AZENTA INC (AZTA)
Health Care · Life sciences equipment and biobanking solutions · NASDAQ
Azenta is a provider of life sciences solutions focused on automated sample management and genomic services for research and clinical development.
What AZENTA INC does
Azenta is a provider of life sciences solutions and laboratory equipment serving the research, clinical diagnostics, and biobanking markets. The company offers automated sample storage and retrieval systems, biopreservation equipment, and related software solutions for managing biological samples. Azenta operates through multiple business segments including equipment manufacturing and service offerings for customers in pharmaceutical, biotechnology, and healthcare research institutions.
Themes: Life sciences equipment, Biobanking / sample storage, Laboratory automation, Biopreservation, Clinical diagnostics
Fundamentals
- Price$32.88 as of 2026-08-24 close
- Market cap$1.4B as of 2026-08-24
- 1-year return+4.2% 2025-08-22 close $31.55 → 2026-08-24 close $32.88
- P/En/a negative earnings
- Net margin-29.9% as of 2026-08-24
- Gross margin+43.9% as of 2026-08-24
- ROE-10.7% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-5.9% as of 2026-08-24
- Revenue CAGR (3y)+2.2% SEC XBRL
- Beta1.32 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
Dividend: 1-year non-decreasing per-share dividend streak (SEC XBRL).
How AZTA compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which AZTA reported a dividend payment is FY2022, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2022 ratio would not describe AZTA today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2022) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How AZENTA INC looks technically
AZENTA INC (AZTA) is trading 31.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 103 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 53, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 79, in overbought territory (above 70). It just made a new 20-day high, its first since 2026-02-02, pushing above its recent trading range.
Trend
9
| Distance from the 200-day | it is trading 31.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +31.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $27.83 | $27.83 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $28.43 | $28.43 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 44 calendar days ago — the swings before that are what the structure reading is measured on | 44 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 24.25. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 103 trading days ago — a "death cross", a bearish long-term signal | 103 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 31.5% above | +31.5% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 53, with buyers in control | 53.3 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 79, in overbought territory (above 70) | 78.6 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($29.06 to $37.49) — its "stochastic" reading is 99 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 98.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 23 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $41.73 | $41.73 |
|---|---|---|
| From the 52-week high | it is 10.4% below its 52-week high (its highest price of the past year) | -10.4% |
| Above the 52-week low | it is 134.8% above its 52-week low (its lowest price of the past year) | +134.8% |
| Below the 52-week high | it is 10.4% below its highest point of the past year | 10.4% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-02-02, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2026-02-02, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $124.79 (set on 2021-11-09) | $124.79 |
| Given back of the 52-week move | over the past year its closes ranged ($16.02 to $41.01), and it has recovered almost all of its fall from last year’s high — 86% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $31.46 to $32.26. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 85.5% |
| From the all-time high | it is 70.0% below its all-time high | -70.0% |
| Nearest price level | it is trading 2.8% below a resistance level at $38.45 — a price it turned at four times since 2024-11-18, most recently on 2025-12-10. Since 2024-08-21 it has 10 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.8% |
| All-time low | its lowest closing price on record is $2.52 (set on 2008-11-21) | $2.52 |
| Above the all-time low | it is 1384.1% above its all-time low | +1,384% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 56th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.42 between its high and its low — about 3.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.42 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $26.41 and $37.58 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $26.41 – $31.99 – $37.58 |
| Typical daily range (% of price) | its price moves about 3.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.8% |
| Stretch from the 200-day average | it is trading 6.3 daily ranges above its 200-day average price (31.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.99× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 2.2% above the previous close 2 sessions ago and has not traded back through the level it left behind at 32.98 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.2% |
| Gap filled | a 2.9% gap up opened on 2026-08-05 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 12 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +13.4% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 38.3 percentage points (the stock gained 40.7% while the market gained 2.3%) | +38.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 88.3 percentage points (the stock gained 91.4% while the market gained 3.1%) | +88.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 16.7 percentage points (the stock gained 27.7% while the market gained 11.1%) | +16.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 4.9 percentage points (the stock gained 25.3% while the market gained 20.5%) | +4.8% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 50% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 9.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +49.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 47% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $25.43 — a volume-weighted average of daily closes over 154 sessions, not a true tick-by-tick VWAP. | +47.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 12% above the average price paid since it last reported on 2026-08-04 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $33.31 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | +12.3% |
Price levels it has turned at before
AZTA last closed at $37.40 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $38.45 | Resistance | 2.8% above the last close | turned there four times · 2024-11-18 to 2025-12-10 |
| $35.28 | Support | 5.7% below the last close | turned there three times · 2025-03-18 to 2025-07-24 |
| $34.09 | Support | 8.8% below the last close | turned there twice · 2025-12-02 to 2025-12-17 |
| $32.98 | Support | 11.8% below the last close | turned there four times · 2025-10-03 to 2026-01-02 |
| $43.95 | Resistance | 17.5% above the last close | turned there twice · 2024-12-17 to 2025-02-18 |
| $45.23 | Resistance | 20.9% above the last close | turned there twice · 2024-09-11 to 2025-03-10 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $24.25.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $29.53 and $32.79 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $24.25.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.17 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$34.80 range $33.00 – $37.00; median $35.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AZTA
- Consensus EPS estimate$0.164 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Material weaknesses in internal control over financial reporting requiring ongoing remediation","Dependence on key suppliers and vendors with potential supply chain disruption risks","Significant revenue decline (down 5.91% YoY) and ongoing unprofitability with negative net margins (-29.88%) indicating operational challenges and integration difficulties following acquisitions"]
What changed in the latest 10-Q
AI-assisted comparison of AZTA's 10-Q filed 2026-05-08 against the prior one filed 2026-02-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-08) adds disclosure of financial statement errors identified during fiscal 2025 preparation and notes they were not material individually or in aggregate
- Newer filing adds reference to Note 20 'Revision of Previously Issued Unaudited Quarterly Information' in 2025 Annual Report on Form 10-K
- Newer filing (2026-05-08) adds new section 'Acquisition of UK Biocentre' disclosing March 4, 2026 acquisition of UK Biocentre Limited for approximately $27.5 million net of cash acquired
- Newer filing updates MD&A organization to reference 'three and six months ended March 31, 2026 and 2025' instead of 'three months ended December 31, 2025 and 2024'
- Newer filing adds disclosure that Thelema informed company on March 27, 2026 that it had not yet secured required financing and transaction did not close by March 31, 2026
- Removed:
- Older filing (2026-02-05) references 'three months ended December 31, 2025 and 2024' which is replaced in newer filing with 'three and six months ended March 31, 2026 and 2025'
- Older filing states Thelema 'is expected to pay the remaining $54.0 million on or before March 31, 2026, at which time the sale will be complete' - this language is removed in newer filing
- Reworded:
- Older filing uses quotation marks around 'MD&A' and 'Share Purchase Agreement'; newer filing uses 'or' conjunction instead
- Older filing states errors were identified 'in connection with the preparation of the fiscal year 2025 consolidated financial statements'; newer filing uses identical language but specifies figures revised were 'for the three and six months ended March 31, 2025' versus older filing's 'for the three months ended December 31, 2024'
- Employee count changed from 'approximately 3,000 full-time employees, part-time employees and contingent workers worldwide as of December 31, 2025' in older filing to 'approximately 2,900 full-time employees, part-time employees and contingent workers worldwide as of March 31, 2026' in newer filing
- Sales countries changed from 'approximately 87 countries' in older filing to 'approximately 83 countries' in newer filing
- Older filing's Thelema financing language changed from expectation of completion by March 31, 2026 to disclosure that financing was not secured and closing did not occur by that date
- Notes:
- Newer filing text is truncated at 'UK Biocentre is a provi' making full assessment of UK Biocentre acquisition section impossible
- Older filing text is truncated at 'Segments' and 'gene seque' preventing full comparison of later sections
Risk Factors
- Added:
- Newer filing (2026-05-08) adds reference to 'including this Quarterly Report on Form 10-Q' in the forward-looking statements section when referencing SEC filings
- Removed:
- Older filing (2026-02-05) contains language 'our dependence on key suppliers or vendors to obtain services for our business on acceptable terms (including the impact of supply chain disruptions), general economic conditions,' which is removed in newer filing (2026-05-08)
- Older filing (2026-02-05) references 'quarterly reports on Form 10-Q and current reports on Form 8-K' while newer filing (2026-05-08) removes 'and current reports on Form 8-K' reference
- Reworded:
- Table of contents page numbers changed: Item 1A Risk Factors moved from page 45 to page 50; Item 2 moved from page 45 to page 51; Item 5 moved from page 45 to page 51; Item 6 moved from page 46 to page 52; Signatures moved from page 47 to page 53 (newer filing 2026-05-08 vs older filing 2026-02-05)
- Balance sheet date changed from 'December 31, 2025' in older filing to 'March 31, 2026' in newer filing, reflecting different quarterly periods
- Notes:
- The provided text is truncated at the balance sheet section and does not include the complete Risk Factors section (Item 1A), so comparison is limited to boilerplate language and forward-looking statements section
- Financial data differs between filings due to different reporting periods (Q1 FY2026 ended March 31, 2026 vs Q1 FY2025 ended December 31, 2025), not document revisions
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days.
- Last 30 days1 buy ($8096) · 0 sells — 1 buying insider
- Last 90 days1 buy ($8096) · 0 sells — 1 buying insider
- Last 180 days2 buys ($171896) · 0 sells — 2 buying insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-31. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AZTA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for AZTA from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding AZTA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 9,084,338
- Reported value $191,952,072
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AZTA had 5,339,160 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AZTA had 12.2% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.36 days to cover at the same settlement.
- Reported short interest (shares) 5,339,160
- Short interest (% of shares outstanding) 12.2%
- Prior settlement (shares) 6,032,546
- Reported change -11.49%
- Days to cover (reported) 9.36
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Thermo Fisher Scientific (TMO)
- Danaher (DHR)
- Brooks Automation (BRKS)
- Hamilton Company
- Avantor (AVTR)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AZTA vs…
AZENTA INC is found in…
Frequently asked questions
What does AZENTA INC (AZTA) do?
Azenta is a provider of life sciences solutions and laboratory equipment serving the research, clinical diagnostics, and biobanking markets. The company offers automated sample storage and retrieval systems, biopreservation equipment, and related software solutions for managing biological samples. Azenta operates through multiple business segments including equipment manufacturing and service offerings for customers in pharmaceutical, biotechnology, and healthcare research institutions.
What sector is AZENTA INC (AZTA) in?
AZENTA INC (AZTA) is classified in the Health Care sector. Its industry is Life sciences equipment and biobanking solutions. It trades on NASDAQ.
Does AZTA pay a dividend?
No — AZENTA INC (AZTA) does not currently pay a dividend (market data, as of 2026-08-24). Informational only — not financial advice.
Who are AZENTA INC's (AZTA) competitors?
Notable peers of AZENTA INC (AZTA) include Thermo Fisher Scientific, Danaher, Brooks Automation, Hamilton Company and Avantor. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in AZTA?
Yes — we hold 4 matched STOCK Act disclosures for AZTA from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is AZENTA INC (AZTA) overbought or oversold right now?
AZENTA INC (AZTA) is currently in overbought territory (its 14-day RSI is 79, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AZTA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.